Saudi's Al Hammadi to acquire 35% of Sudair Pharmaceutical
Saudi Authority approves the conclusion of the economic concentration process
A Saudi trader monitors stocks at the Saudi stock market in Riyadh, Saudi Arabia, January 8, 2020.
By Staff Writer, Arab News
Saudi Arabia - The General Authority for Competition announced its approval for the conclusion of the economic concentration process between Al Hammadi Company for Development and Investment and Sudair Pharmaceutical Co.
Al Hammadi for Development and Investment acquired 35 percent of Sudair Pharmaceuticals’ shares.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
Get Zawya's daily newsletter for insightful and exclusive Middle East perspectives on business and finance. SUBSCRIBE NOW